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Abstract
Epigenetic regulation of genes involves the coordination of DNA methylation and histone modifications to maintain
transcriptional status. These two features are frequently disrupted in malignancy such that critical genes succumb to
inactivation. 5-aza-29-deoxycytidine (5-aza-dC) is an agent which inhibits DNA methyltransferase, and holds great potential
as a treatment for cancer, yet the extent of its effectiveness varies greatly between tumour types. Previous evidence
suggests expression status after 5-aza-dC exposure cannot be explained by the DNA methylation status alone.
Aim: We sought to identify chromatin changes involved with short and long term gene reactivation following 5-aza-dC
exposure. Two colorectal cancer cell lines, HCT116 and SW480, were treated with 5-aza-dC and then grown in drug-free
media to allow DNA re-methylation. DNA methylation and chromatin modifications were assessed with bisulfite sequencing
and Chromatin Immuno-Precipitation analysis.
Results: Increased H3 acetylation, H3K4 tri-methylation and loss of H3K27 tri-methylation were associated with reactivation.
Hypermethylated genes that did not show increased acetylation were transiently expressed with 5-aza-dC treatment before
reverting to an inactive state. Three reactivated genes, CDO1, HSPC105 and MAGEA3, were still expressed 10 days post 5-
aza-dC treatment and displayed localised hypomethylation at the transcriptional start site, and also an increased enrichment
of histone H3 acetylation.
Conclusions: These observations suggest that hypomethylation alone is insufficient to reactivate silenced genes and that
increased Histone H3 acetylation in unison with localised hypomethylation allows long term reversion of these
epigenetically silenced genes. This study suggests that combined DNA methyltransferase and histone deacetylase inhibitors
may aid long term reactivation of silenced genes.
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Introduction
The human genome contains approximately 3 billion base pairs
of DNA [1] that require strategic packaging into a compact, yet
dynamic structure. Condensation is achieved with the supercoiling
of ,147 bp DNA around an octamer of histone proteins (two
copies of each H2A, H2B, H3 and H4) to form a nucleosome [2]
which impedes accidental gene expression and increases the
dependence of transcriptional activators [3]. Transcriptional re-
pression can be mediated by DNA methylation and is assisted by
extensive modifications at highly conserved lysine residues on the
tails of histone proteins. Lysine acetylation facilitates transcription
by weakening the association of the histone and DNA [4] and
allows transcription factor binding [5]. Lysine methylation is more
complex and can be associated with both active and repressed
regions of DNA, and may be present in mono-, bi-, and tri-
methylated forms [6]. For instance, trimethylation of histone H3
lysine 4 (H3K4me3) is an active mark [7] whilst methylation of
H3K9 and H3K27 appears at transcriptionally silent gene
promoters [7,8].
Aberrant epigenetic silencing of genes can initiate malignancy
and frequently appears in addition to genetic alterations, con-
tributing to disease progression in several forms of cancer [9,10,
11]. In addition, aberrant hypomethylation of proto-oncogenes
can lead to their activation [12,13] Reduced expression of
numerous genes due to epigenetic silencing correlates with poor
prognosis in many forms of malignancy such as lung [14],
melanoma [15], breast [16], gastric [17] and colon [18]. Rare
instances of soma-wide mono-allelic methylation of MLH1 have
been shown to arise via germline transmission [19]. In addition,
heritable copy-number variations can result in transcriptional read
through and in-cis methylation when adjacent to key genes [20].
These mechanisms offer an explanation of why some families are
at a higher risk of disease development despite not carrying an
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such families could benefit from early detection of aberrant epi-
genetic marks at genes which confer an elevated risk of a particular
disease. With an increasing awareness of epigenetic abnormalities
in disease, counteracting these changes with methyltransferase
inhibitors such as 5-aza-29-deoxycytidine (5-aza-dC) would appear
to be a potentially effective treatment. In reality, this treatment is
not effective in a specific group of tumour types [21], which may
be due to reactivated genes reverting to a silenced state upon
cessation of treatment.
We have previously identified the reactivation of numerous
genes in colorectal cancer cell lines following treatment with the
demethylating agent 5-aza-dC [22]. Upon removal of the drug
and ten days of growth, some of these genes remained highly
expressed, suggesting a reversal of the transcriptional status of
these genes. Although reduced by 5-aza-dC, the changes in DNA
methylation did not correlate with the levels of expression in the
group of genes analysed, indicating other epigenetic modifications
were controlling transcription. The genes selected for analysis were
examined due to their involvement in a range of tumour types and
possible use as biomarkers in these tumours [23,24,25], and/or
due to their strong re-expression and pattern of gene expression
following 5-aza-dC in colorectal cancer cells [22]. CDKN2A was
chosen specifically as it is frequently repressed in colorectal cancer
tumours [26]. These genes may represent important genes in the
epigenetic development of a number of tumour types. In this study
we have characterised the changes of DNA methylation and
chromatin state which allow for either a long or short term
reactivation of expression following 5-aza-dC exposure.
Methods
Cell Culture
Triplicate cultures of HCT116 and SW480 cells were grown in
DMEM media supplemented with 10% foetal calf serum (Sigma-
Aldrich, St Louis, MO, USA) at 37uC and 5% CO2. Cells were
treated with 5-aza-29-deoxycytidine (Sigma-Aldrich) as previously
described [22]. DNA and RNA were extracted from untreated
cells, 5-aza-dC treated cells (72 h of treatment), and at 4 and 10
days after cessation of treatment (Day 4 and 10 of re-methylation).
The cells were originally obtained from the ATCC and were
authenticated using the Identifiler DNA identification kit (Applied
Biosystems, Foster City, CA, USA) according to manufacturer’s
instructions.
Global methylation
Global methylation was assessed as described previously [22].
Briefly, 50 mg of DNA was enzymatically digested with Nuclease
P1 (US Biological, Swampscott, MA, USA) followed by chro-
matographic separation on a Varian Star Chromatography work-
station with a Supelcosil LC-18-DB column (Sigma-Aldrich).
Absorbance was monitored at 278 nm and peak areas were quan-
tified with Star Reviewer Software (Varian, Palo Alto, CA, USA).
The 5-methylcytosine content was expressed as a percentage of the
total cytosine pool after correction for extinction co-efficients.
Bisulfite Sequencing
DNA was converted in duplicate using a Qiagen Epitect
Bisulfite conversion kit (Qiagen, Valencia, CA, USA) using 2 mgo f
phenol-chloroform purified DNA. Samples were eluted in 30 mL
of elution buffer and an aliquot was diluted 1:3 prior to PCR and
stored at 4uC, whilst the remaining fraction was stored at 220uC.
CpG islands surrounding the transcription start site of genes were
targeted in PCR analysis using the primers listed in Table S1.
Sequencing reactions were performed in duplicate and were
analysed on an ABI 3730 sequencer. Data analysis was carried out
using Sequence Scanner software (Applied Biosystems). The
percentage methylation at each CpG was determined by dividing
the cytosine peak by the combined heights of the cytosine and
thymine peaks as described previously [27].
Real Time PCR Analysis of gene expression
RNA was converted to cDNA using Superscript II (Invitrogen)
and random primers (Promega) according to manufacturer’s in-
structions. Reactions were performed in triplicate using primers
listed in Table S1, 26 SYBR Green (Applied Biosystems) in an
ABI PRISM 7500 PCR machine (Applied Biosystems). CT values
were determined automatically by Sequence Detection Software
version 1.4 and final calculations were expressed as fold differences
compared to B-actin using the DDCT method. Genes with un-
detected expression were assigned a CT value of 40. Error bars in
expression figures represent the standard error.
Chromatin Immunoprecipitation (ChIP) and Analysis
Briefly, the crosslinking of DNA with protein and cell lysis was
performed using the EZ-Magna ChIP A Kit (Upstate/Millipore)
according to the manufacturer’s instructions. Sonication was
performed using 8630-second cycles at 60% duty cycle in an ice
bath and samples were further cooled for 30 seconds in between
sonication cycles. Chromatin Immunoprecipitation was performed
as previously described [28] with slight modifications. Antibodies
were obtained from Upstate (Catalog numbers; a-H3Ac 06-599,
a-H3K4me3 07-473, a-H3K9me3 17-625, a-H3K27me3 17-622)
with the exception of the Rabbit IgG non-specific antibody from
Santa Cruz Biotechnology (Catalog number SC2027). Antibody
quantities per reaction were determined in preliminary experi-
ments and were 5 mL for a-acetyl H3, 5 mL for a-H3K4me3, 4 mL
for a-H3K9me3, 4 mL for a-H3K27me3. 5 mL of Rabbit IgG was
added to negative control samples. Cross links were reversed with
the addition of 20 mL Proteinase K (Promega) and incubated at
62uC for 3 h with shaking. Recovered DNA was then purified
using a PCR clean up kit (Qiagen, Valencia, CA, USA).
Real time PCR analysis of immunoprecipitated chromatin
DNA was quantified using the DNA Quantitation System
(Promega) according to the manufacturer’s instructions, and
measurements were taken using a TD 20/20 luminometer (Turner
Designs, Sunnyvale, CA, USA). The real-time PCR reactions were
performed using 200 rg of DNA template with SYBR Green 26
mastermix (Applied Biosystems) and primers listed in Table S1.
Reactions were performed in triplicate and carried out using an
ABI PRISM 7500 PCR machine (Applied Biosystems). CT values
were determined automatically by Sequence Detection Software
version 1.4 (Applied Biosystems) and the final values were
expressed as a percentage of the input fraction. Error bars in
chromatin change figures represent the standard error.
Statistical Analysis
Standard deviations were calculated and a T-test was employed
to compare expression levels and histone modification levels in
drug treated cells against untreated cells. P-values less than 0.05
were considered to be statistically significant.
Results
Genomic DNA Methylation with 5-aza-dC treatment
Global methylation levels decreased following 5-aza-dC treat-
ment by 53% and 59% in the HCT116 and SW480 cell lines
Hypomethylation, Acetylation and Gene Reactivation
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compared with cells that were mock treated which did not
undergo demethylation (HCT116 p-value=0.003, SW480 p-
value=0.017). Continued incubation of cells for a further ten days
after treatment in drug free media allowed DNA re-methylation
and genomic levels increased, but did not return to the same level
as observed prior to treatment in this period.
Gene Specific methylation and re-expression with 5-aza-
dC treatment
Using genome wide expression arrays we have previously
identified patterns of gene expression following 5-aza-dC treat-
ment [22]. The same genes were again examined in this study to
allow characterisation of histone modifications. In this experiment,
expression was determined with quantitative PCR and genes were
then classified into five categories; ‘always-expressed’ (expression
detected at all time points), ‘up-regulated’ (two-fold in expression
after 5-aza-dC treatment), ‘long term reactivated’ (undetected in
untreated cells, but expressed after treatment as well as four and
ten days after drug exposure (based on a CT value of 40 for
undetectable transcripts)), ‘short term reactivated’ (same as ‘long
term reactivated’ with the exception of day four and/or ten
expression which was required to be ,100-fold above the level of
untreated cells), or ‘other’ (any other pattern of gene expression).
The three genes which were reactivated for a short period only
(CXCL6 and ZFP3 in HCT116 cells and CDKN2A in SW480
cells) were all hypermethylated across the assayed region of their
CpG islands. The expression pattern of these genes was markedly
different in the other of the two cell lines; here, these genes showed
very little or low methylation at the transcription start site (TSS)
and were either expressed continually or became up-regulated
(figure 2). The genes which remained highly expressed after
reactivation (CDO1, HSPC105, MAGEA3) displayed unique
methylation profiles and featured a hypomethylated CpG site
adjacent to the transcription start site (TSS) as shown in figure 3.
The CpG island specific demethylation after treatment was 10–
15% at most,, therefore only untreated methylation patterns are
shown in Figure 2 and 3. Data for the four time points is shown in
Figure S1 for the MAGEA3 gene which displayed the largest gene
associated decrease in DNA methylation. An example of the direct
sequencing chromatograms of MAGEA3 are shown in Figure S2.
Genes determined to be ‘always-expressed’ displayed a max-
imum of 50% methylation at the TSS which suggests mono-allelic
methylation, and up-regulated genes displayed varying patterns of
methylation. The MLH1 gene was expressed in both cell lines and
methylation was not detected in the TSS associated CpG island
(data not shown). Conversely, a variant of DICER1 was not
expressed in either cell line at any time point as determined by
microarray analysis and the absence of its expression was
confirmed by quantitative PCR. DICER1 is not associated with
a CpG island, therefore bisulfite sequencing analysis was not
performed. CDKN2A was expressed in HCT116 and showed
partial methylation at the TSS. The corresponding region in
SW480 cells was hypermethylated and expression was classified as
short term reactivated after treatment.
Continued incubation of cells in drug free media allowed re-
methylation of the DNA, which returned to original levels at
promoter CpG islands. Gene expression was not necessarily
affected by the return of promoter methylation however, and
expression of the CDO1, HSPC105 and MAGEA3 genes in
SW480 cells remained high ten days after 5-aza-dC treatment.
These genes displayed unique CpG island methylation patterns
that feature hypomethylated CpG sites adjacent to the TSS. As
methylation levels at promoter CpG islands did not accurately
reflect the expression of the genes studied, we sought to examine
the patterns of histone modifications at the respective CpG islands
that may account for high levels of expression.
Chromatin modifications after 5-aza-dC exposure
Chromatin Immunoprecipitation and q-PCR revealed that
Histone H3Ac and H3K4me3 were features associated with
expressed genes such as GAPDH and MLH1 and repressed genes
Figure 1. Genome wide methylation levels and 5-aza-dC treatment. Genomic methylation levels decreased significantly in both cell lines
following 5-aza-dC exposure. Genomic methylation levels were gradually restored over the next ten days of drug-free growth where they were
approaching pre-drug treatment levels.
doi:10.1371/journal.pone.0023127.g001
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which were absent from constitutively expressed genes.. ChIP
results are summarised in Figure 2 and 3, with p-values listed in
Table 1. Specific changes in chromatin modification are shown in
Figures S3, S4, S5, S6.
Changes to the chromatin proteins following 72 h of exposure
were dependant on the gene expression status. Genes with greater
expression after treatment increased in H3K4me3, while H3Ac
was only associated with genes reactivated for longer periods.
Generally the repressive H3K27me3 marks were reduced after
treatment, with the exception of CXCL6 gene. A comparison of
histone modifications in short term reactivated genes revealed
transient increase of histone H3K4me3 and decreased or stable
level of trimethyl-histone H3 lysine 9 and 27. Despite this, tran-
scription of these genes ten days post treatment was at a similar to
untreated cells. The single most apparent difference between short
and long term reactivated genes was the H3Ac modification.
Genes deemed to be ‘long term reactivated’ revealed an increase
of H3Ac, although not always reaching statistical significance, after
treatment which persisted until ten days after drug treatment.
There was also a trend in long term re-expressed genes where a
reduction in H3K27me3 was observed The up-regulated genes
(CDO1 in HCT116 cells and ZFP3 in SW480) and genes which
were always expressed showed a gain of active chromatin marks
and a loss of repressive histone modifications after 5-aza-dC
exposure.
Discussion
The epigenetic control of gene expression is mediated by DNA
methylation and histone modifications. By altering the DNA
methylation and up-regulating gene expression we can identify
patterns of change in histone protein modifications that accom-
pany the long and short term reactivation of epigenetically silenced
genes. Of particular relevance to this study was the apparent
transcriptional up-regulation of silenced genes that displayed less
than 15% DNA demethylation, where histone modifications are
likely to be involved in the regulation of gene expression in these
instances.
The effect of DNA methylation on gene expression
Regardless of the expression pattern during drug treatment, the
extent of methylation of particular CpG islands remained rela-
tively unchanged compared to genomic levels after 5-aza-dC
exposure. This observation has been made previously, with methy-
lation of repeat sequences likely to contribute to this discrepancy
[22,29]. Another study has shown that DNA methylation increases
at promoters of non-expressed genes when inhibited by doxycy-
cline in a tet-responsive promoter system [30]. Constitutively
expressed genes were hypomethylated on both alleles, or exhibited
CpG island methylation of 50% indicating mono-allelic methyl-
ation, such as the CDKN2A gene in HCT116 cells as previously
shown [31]. Slight demethylation of promoter CpG islands was
induced with 5-aza-dC, yet expression was not necessarily
restricted in some genes when the methylation returned to original
levels. High expression of long term reactivated genes appeared to
be dependent upon pre-existing hypomethylation at the TSS
regardless of whether the adjacent CpG sites were hypermethy-
lated. This result indicates the pattern of methylation rather than
the general level of methylation across the CpG island is crucial to
re-activating silenced genes via interactions with other epigenetic
factors. Hypomethylated CpG sites within hypermethylated
promoters have been identified previously in the Oncostatin M
receptor gene [27], but the effect of this hypomethylation on
transcription was not examined. Why expression of the long term
reactivated genes did not occur in the untreated cells which
displayed a near identical methylation pattern may be explained
by changes in the modifications on the histone proteins.
The effect of histone modifications on gene expression
A snapshot of factors governing gene expression was achieved
with the compilation of CpG island sequencing and chromatin
immuno-precipitation results. Upon the reactivation of numerous
genes and classification of expression, we could distinguish be-
tween the genes based on the methylation and chromatin changes
present. Prior to treatment, transcriptionally inactive genes were
characterised by higher levels of repressive modifications and
lower levels of activating marks. Upon treatment with 5-aza-dC
there was generally an increase to the levels of H3K4me3 and
H3K9me3, whilst H3Ac increased only in some of the genes.
Reductions to H3K27me3 occurred in genes that initially dis-
played this trait. With regards to chromatin modifications, it was
during the drug free growth period that histone acetylation
became the most distinguishable feature between short and long
term reactivated genes. Long term reactivated gene promoters
became increasingly associated with acetylation of histone H3
assisting with gene activation however only reached significant
levels after ten days of drug free growth. Temporarily reactivated
genes did not attract this modification despite a brief period of
expression. It would therefore appear that the introduction of H3
acetylation is a crucial factor in reversing transcriptional status of
an epigenetically silenced gene which is assisted by localised DNA
hypomethylation. With the exception of H3K27me3 at CDKN2A
in SW480 cells, long lasting changes to epigenetic modifications
were not observed in temporarily reactivated genes.
The up-regulation of lowly expressed genes was associated with
increased H3 acetylation and H3K4me3, such as the ZFP3 gene in
SW480 cells. Methylation profiles such as this may indicate an
intermediate between always-expressed genes and the long term
reactivated genes. Co-existing active and repressive marks may
allow a restricted level of transcription, suggesting the control of
expression of these genes is dependent on equilibrium of both
types of modifications.
In the genes examined in this study, the roles of histone H3
acetylation and H3K27me3 were apparent as activating and
repressing marks respectively, however the effect of H3K4me3 and
H3K9me3 did not appear sufficient to alter gene expression on a
long term basis. Following 5-aza-dC exposure, H3K9me3 was
Figure 2. CpG island methylation of short term reactivated genes with respect to different expression types. A – CXCL6 CpG island
methylation; short term v always-expressed. (B) - SW480 cells displayed hypomethylation and CXCL6 was expressed at all time points. (C) - Uniform
hypermethylation of the HCT116 cell line was associated with a short term reactivation of expression. D, E, F – CDKN2A CpG Island methylation;
short term v constant expression. SW480 cells display CDKN2A hypermethylation and were temporarily re-expressed, whilst in HCT116 cells CDKN2A
is ,50% methylated at CpG sites near the TSS, and was expressed at all time points. Asterisks denote significant change compared to untreated cells.
G, H, I – ZFP3 CpG Island methylation; short term v up-regulated expression. SW480 cells showed hypomethylation at CpG sites near the TSS and
expression was up-regulated after 5-aza-dC treatment. ZFP3 remains hypermethylated in HCT116 cells and was temporarily reactivated with 5-aza-dC
treatment . J – Significant changes to histone modifications compared with untreated cells (p,0.05).
doi:10.1371/journal.pone.0023127.g002
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findings that it can also be coupled with gene activation [29,
32,33]. Similarly, H3K4me3 which associates with active regions
of the genome was found at inactive genes, albeit at a reduced
level. Observations of this nature highlight the dynamic nature of
chromatin and possibly suggest an intermediate form of repression
similar to bivalent chromatin surrounding developmental genes
[34] or the effect of neighbouring chromatin that has been detected
because of variations in shearing efficiency during sonication.
Linking DNA methylation, chromatin modifications and
gene expression
The patterns of expression of re-activated and up-regulated
genes can be largely explained with the combination of promoter
methylation analysis and chromatin immuno-precipitation assays.
By observation and comparison of long and short term reactivated
genes, our results show that genes with a localised hypomethyla-
tion at the TSS are more likely to experience an increase of histone
H3 acetylation and remain expressed after 5-aza-dC exposure.
Additionally we observed that specific gene expression was
reactivated without major change in the associated CpG island
methylation and this was independent of nearby hypermethylation
within the same CpG island.
A sequence of events involved with epigenetic reactivation
has been proposed by Litt et al. [35]. The authors state that
reactivation of the HPRT gene required hemi-demethylation of
the promoter, ‘opening’ of chromatin structure, transcription factor
bindingand assembly of the transcriptioncomplex prior to synthesis
of the HPRT RNA. Based on our experiments, we can extend on
this knowledge by suggesting that minor demethylation induced by
5-aza-dCandincreasedH3K4me3allowsinitiationoftranscription.
The role of H3K9 trimethylation is not clear but may be associated
with reactivation in some instances. A loss of repressive marks such
as H3K27me3 can also further increase transcription. Although not
examined here, it is possible MBD2 binding could be lost at this
point which would no longer deter histone acetyltransferase from
the region [36]. Transcription is prolonged if increased acetylation
of histone H3 occurs, otherwise expression is transient and gene
expression is likely to revert to an inactive state.
Methyltransferase Inhibitors in treatment of tumours
Previous studies have shown the genes used in this study suc-
cumb to methylation in other malignancies such as certain forms
of breast [24] and ovarian [37] cancer. Therefore, the reactivation
described in this study may not be limited to colorectal cancer, but
also other tumour types where reversal of epigenetic repression
may be of therapeutic benefit. Efficacy of 5-aza-dC as a treat-
ment is limited to certain tumour types, however, what causes a
favourable outcome from 5-aza-dC treatment is unknown. Its
success may lie with the methylation pattern at currently un-
identified target genes and the drugs ability to reactivate silenced
genes over a longer period of time. Therefore, our results suggest
that repressed genes displaying localised TSS hypomethylation
may be reactivated with combined methyltransferase/histone
deacetylase inhibitor treatment. Increased acetylation at hyper-
methylated transcription start sites which lead to long term
reactivation of anti-proliferative genes may be beneficial in the
treatment of tumours when this information is known. This
Figure 3. Promoter CpG Island methylation of long term reactivated genes. A, B, C – CDO1 CpG Island methylation; long term v short term
expressed. Sequencing analysis revealed CpG sites near the TSS in SW480 cells have lower methylation and displayed long term expression compared
with HCT116 cells which are uniformly hypermethylated at CDO1 and experienced an up-regulated pattern of expression. D, E, F - HSPC105 CpG
Island methylation; always-expressed v long term expressed. The SW480 cell line shows localised hypomethylation at the TSS and can remain
expressed ten days post treatment. The HCT116 cell line is hypomethylated at the HSPC105 promoter and is continually expressed. G, H, I – MAGEA3
CpG Island methylation; always-expressed v long term re-expressed. SW480 cells show localised hypomethylation at the TSS and are expressed ten
days post treatment. HCT116 cells show ,50% methylation at the TSS and MAGEA3 is expressed at all time points. J – Significant changes to histone
modifications compared with untreated cells (p,0.05).
doi:10.1371/journal.pone.0023127.g003
Table 1. P-values for changes to histone modifications in comparison to untreated cells.
Gene Cell line H3Ac H3K4me3 H3K9me3 H3K27me3
d0 d4 d10 d0 d4 d10 d0 d4 d10 d0 d4 d10
CDKN2A HCT116 0.169 0.518 0.627 0.240 0.034* 0.076 0.724 0.209 0.339 0.019* 0.803 0.741
SW480 0.519 0.338 0.515 0.801 0.846 0.047* 0.946 0.756 0.582 0.010* 0.245 0.034*
CXCL6 HCT116 0.372 0.271 0.156 0.083 0.052 0.052 0.154 0.784 0.355 0.068 0.620 0.592
SW480 0.359 0.185 0.274 0.167 0.025* 0.063 0.223 0.076 0.113 0.238 0.086 0.184
ZFP3 HCT116 0.312 0.182 0.416 0.003* 0.269 0.219 0.588 0.049* 0.954 0.767 0.845 0.664
SW480 0.464 0.271 0.035* 0.472 0.007* 0.031* 0.202 0.064 0.088 0.310 0.684 0.827
CDO1 HCT116 0.683 0.596 0.821 0.488 0.488 0.396 0.479 0.866 0.147 0.759 0.431 0.478
SW480 0.280 0.162 0.080 0.129 0.403 0.823 0.879 0.509 0.826 0.354 0.141 0.199
HSPC105 HCT116 0.943 0.123 0.020* 0.365 0.499 0.691 0.343 0.682 0.059 0.807 0.310 0.725
SW480 0.107 0.144 0.008* 0.271 0.115 0.522 0.328 0.421 0.274 0.359 0.288 0.988
MAGEA3 HCT116 0.314 0.254 0.267 0.934 0.382 0.248 0.992 0.600 0.670 0.969 0.686 0.261
SW480 0.317 0.074 0.022* 0.073 0.091 0.165 0.304 0.826 0.427 0.897 0.334 0.285
Significant changes compared to untreated cells are marked with an asterisk (p=0.05). Results are based on triplicate cell cultures and triplicate measurements for each
time point.
doi:10.1371/journal.pone.0023127.t001
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apoptotic effect of methyltransferase and histone deacetylase
inhibitors [28,38].
Conclusion
Analysis of the chromatin at the promoter of the genes in this
study suggests that existing hypomethylation following (but not
necessarily induced by) 5-aza-dC treatment, aids histone H3
acetylation, either directly or indirectly. The combination of
hypomethylation of CpG sites at the TSS and H3 acetylation
result in stable reactivation of the genes studied here. The results of
this study highlight the epigenetic features which need to be
modified with regard to the reversal of transcriptional status of
genes in the treatment of disease. A more strategic approach will
lead to the development of epigenetic therapies rather than the use
of epigenetic-modifying drugs as cytotoxic therapies.
Supporting Information
Figure S1 Methylation of MAGEA3 in SW480 cells
treated with 5-aza-dC. Bisulfite sequencing PCR was per-
formed at each time point and plotted to show changes before and
after 5-aza-dC treatment, The MAGEA3 gene showed the greatest
demethylation of all the genes assayed, with a decrease of 10–15%
at several CpG sites near the TSS gene.
(TIF)
Figure S2 Methylation at the MAGEA3 Transcription
Start Site. A - Promoter methylation across the MAGEA3 CpG
island. The red bar indicates the region of sequence shown in B
and C. B – Methylation at the MAGEA3 TSS in SW480 cells.
Direct sequencing of bisulfite PCR products causes dual C and T
peaks at CpG sites, and are representative of methylated and non-
methylated alleles respectively. The CpG site adjacent to the TSS
shows a greater proportion of T alleles (representing unmethylated
cytosine) indicating hypomethylation, while nearby CpG sites
show increased cytosine peaks and higher methylation levels.
Arrows indicate CpG sites, boxed T’s indicate position of non-
CpG cytosine and underlined sequence represents the transcrip-
tion start site. C – CpG sites in the HCT116 cell line are greater
than 50% methylated.
(TIF)
Figure S3 HCT116 chromatin changes at CDO1,
HSPC105 and MAGEA3 transcription start sites. Mock
treatments are plotted with white data points and 5-aza-dC treated
cells are plotted with black data points. The y-axis values represent
percentage input, whilst x-axis values represent the four time-
points of cell culture. Asterisks denote significant changes (t-test,
p=,0.05) compared to the untreated point.
(TIF)
Figure S4 SW480 chromatin changes at CDO1,
HSPC105 and MAGEA3 transcription start sites. Mock
treatments are plotted with white data points and 5-aza-dC treated
cells are plotted with black data points. The y-axis values represent
percentage input, whilst x-axis values represent the four time-
points of cell culture. Asterisks denote significant changes (t-test,
p=,0.05) compared to the untreated point.
(TIF)
Figure S5 HCT116 chromatin changes at CDKN2A,
CXCL6 and ZFP3 transcription start sites. Mock treat-
ments are plotted with white data points and 5-aza-dC treated cells
are plotted with black data points. The y-axis values represent
percentage input, whilst x-axis values represent the four time-
points of cell culture. Asterisks denote significant changes (t-test,
p=,0.05) compared to the untreated point.
(TIF)
Figure S6 SW480 chromatin changes at CDKN2A,
CXCL6 and ZFP3 transcription start sites. Mock treat-
ments are plotted with white data points and 5-aza-dC treated cells
are plotted with black data points. The y-axis values represent
percentage input, whilst x-axis values represent the four time-
points of cell culture. Asterisks denote significant changes (t-test,
p=,0.05) compared to the untreated point.
(TIF)
Table S1 Primer sequences used in Bisulfite PCR/
sequencing and ChIP qPCR and expression qPCR.
(DOC)
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